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S U M M A R Y
Background: This study compared the investigational quadrivalent meningococcal CRM197 conjugate
vaccine, MenACWY-CRM, with licensed quadrivalent polysaccharide (MPSV4) and conjugate
(MenACWY-D) meningococcal vaccines.
Methods: In this phase III multicenter study, 2505 adults (aged 19–55 years) were randomized to receive
either MenACWY-CRM or MenACWY-D, and 326 adults (aged 56–65 years) were randomized to receive
either MenACWY-CRM or MPSV4. Sera obtained pre-vaccination and at 1-month post-vaccination were
tested for serogroup-speciﬁc serum bactericidal activity using human complement (hSBA) for
immunogenicity non-inferiority and superiority analyses.
Results: The vaccines in all groups were well tolerated. In the 19–55 years age group, post-vaccination
geometric mean titers (GMTs) were consistently higher forMenACWY-CRM than forMenACWY-D for all
four serogroups. MenACWY-CRM was non-inferior to MenACWY-D for all serogroups, and superior for
serogroup Y. In the 56–65 years age group, post-vaccination GMTs were 1.2- to 5.4-fold higher for
MenACWY-CRM than for MPSV4 for the four serogroups.
Conclusions: MenACWY-CRM is well tolerated and immunogenic in adults aged 19–65 years, with at
least non-inferior immunogenicity compared with the currently licensed meningococcal vaccines.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Meningococcal disease caused by Neisseria meningitidis is a
major cause of morbidity and mortality worldwide.1 The highest
incidence ofmeningococcal disease is in infants aged< 12months,
and a second peak in incidence often occurs in adolescents.2
Although the incidence of meningococcal disease is highest in
infants, 50% of meningococcal disease in Europe3 and 62% of
meningococcal disease in the USA occurs among persons aged10
years and 11 years, respectively.2 In other regions, such as Latin
America, the adolescent peak is not so obvious,with approximately
25% of meningococcal disease cases occurring among persons 15
years of age.4 Furthermore, case-fatality rates are higher in young
adults aged 15–24 years (22.5%) and in adults aged >25 years
(16.5%), than in children aged <15 years (4.6%).5* Corresponding author. Tel.: +54 11 4803 0720; fax: +54 11 4802 3913.
E-mail address: dstamb@funcei.org.ar (D. Stamboulian).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.03.017The global epidemiology of meningococcal serogroups is
dynamic and unpredictable, and can differ by region. In 2007,
USA Active Bacterial Core Surveillance data showed that menin-
gococcal serogroups B, C, and Y accounted for 25%, 30%, and 37% of
isolates in that year, respectively,6 with a markedly increased
contribution from serogroup Y, which was <5% in the early
1990 s.7 Similarly, in Colombia between 1994 and 2002, and
between 2003 and 2006, serogroup Y increased from accounting
for 2.2% of all invasive meningococcal disease to over 29.5%.8
Epidemics in Africa and elsewhere in the world have most
frequently been caused by serogroup A, and more recently
serogroup W-135.9 The recent emergence of serogroup W-135
was underscored by an outbreak in 2000 that was associated with
theHajj – thiswas the ﬁrst recognition of the potential for outbreak
in this serogroup.10 In Brazil, the prevalence of serogroup W-135
increased signiﬁcantly in the period 2003–2005.11 An unprece-
dented incidence of serogroup X was reported in Niger, Africa in
2006.12 Serogroups B and C are predominant in most regions,
including Europe and Latin America.13ses. Published by Elsevier Ltd. All rights reserved.
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minant surface proteins, coupled with the poor immunogenicity of
the capsular polysaccharides, has prevented the successful
introduction of a broadly protective serogroup B meningococcal
vaccine.14 This will take some years and until this is possible, the
best option for protection is offered by quadrivalent (meningo-
coccal serogroups A, C,W-135, and Y) vaccination. Of the two types
of licensed quadrivalent meningococcal vaccine, only the plain
polysaccharide vaccine is licensed outside North America, and it
remains the only vaccine anywhere in theworld that is licensed for
adults aged >55 years. Such unconjugated meningococcal
polysaccharide vaccines have been shown to be well tolerated
and immunogenic in children >2 years of age and adults,13 but are
poorly immunogenic in children aged <2 years.15 Polysaccharide
vaccines do not promote T cell-dependent responses, and therefore
do not induce immunologic memory.16,17 They also provide a
limited duration of protection18 and do not confer sustainable
reduction of nasopharyngeal carriage of N. meningitidis.19,20
In comparison, conjugated meningococcal vaccines have been
shown to contribute to the control of meningococcal infection by
indirect protection or herd immunity, by reducing the attack rate
in the unvaccinated population,21 and can generate T cell-
dependent responses, therefore inducing immunologic memory.22
An investigational quadrivalent meningococcal conjugate
vaccine (MenACWY-CRM, Novartis Vaccines, Bellaria-Rosia, Italy),
which includes Corynebacterium diphtheriae cross-reactive mate-
rial (CRM197), a naturally occurring non-toxicmutant of diphtheria
toxin, has been shown to be well tolerated and immunogenic in
infants,23,24 children,25 and adolescents.26 In two studies carried
out in adolescents in the USA, MenACWY-CRM elicited a non-
inferior immune response compared with an unconjugated
meningococcal polysaccharide vaccine, Menomune (MPSV4;
Sanoﬁ Pasteur Inc., Swiftwater, PA, USA),26 and generated higher
antibody titers to all four serogroups than with a polysaccharide–
protein conjugate vaccine, Menactra (MenACWY-D; Sanoﬁ Pasteur
Inc., Swiftwater, PA, USA), conjugated to denatured diphtheria
toxoid carrier proteins.27
In the present study in Latin America, the safety and
immunogenicity of MenACWY-CRM were compared with the
licensed vaccines to establish non-inferiority: MenACWY-D in
subjects aged 19–55 years and MPSV4 in subjects aged 56–65
years (as MenACWY-D is not licensed for use in subjects>55 years
of age).
2. Methods
A phase III, observer-blind, multicenter, randomized, controlled
study was conducted in Argentina and Colombia to evaluate the
safety and immunogenicity of MenACWY-CRM in healthy subjects
aged 19–65 years. Ethics committee approval of the protocol was
obtained before enrollment, and written informed consent was
obtained from each subject. The study was performed in
accordance with the current Good Clinical Practice and Interna-
tional Conference on Harmonisation guidelines.
2.1. Subjects
Subjects were approached via posters displayed in medical
clinics. Healthy subjects aged 19–65 years were eligible for
inclusion in the study. Subjects were excluded from the study if
they had previously received meningococcal vaccine; had been
vaccinated with any licensed vaccines 1 month before enroll-
ment; had a previous or suspected disease caused by
N. meningitidis; had received any investigational agents or vaccines
90 days before enrollment; had any serious acute, chronic, orprogressive disease; or had a known or suspected impairment/
alteration of immune function.
2.2. Vaccines and vaccinations
A total of 2831 subjects were enrolled and randomized in the
study. Of these, 2505 subjects aged 19–55 years were randomly
assigned to receive either MenACWY-CRM or MenACWY-D.
Immunogenicity testing was performed for the ﬁrst 200 subjects
in both the 19–34 years and the 35–55 years age groups; these
subjects were randomized in a 1:1 ratio. The subsequent subjects
were randomized in a 2:1 ratio to receive MenACWY-CRM or
MenACWY-D. The 326 subjects aged 56–65 years were random-
ized in a 2:1 ratio to receive either MenACWY-CRM or MPSV4, and
the ﬁrst 225 subjects were tested for immunogenicity.
All subjects received a single dose (0.5 ml) of one of the three
vaccines, administered intramuscularly in the left upper deltoid
area (MenACWY-CRM or MenACWY-D), or subcutaneously in the
left upper arm (MPSV4). Each dose of MenACWY-CRM consisted of
two components: 10 mg of lyophilizedmeningococcal serogroup A
capsular polysaccharide, conjugated to CRM197 (MenA), and 5mg
of capsular polysaccharide of serogroups C, W-135, and Y,
conjugated to CRM197 in 0.5 ml of phosphate-buffered saline,
which was used to reconstitute the lyophilized MenA component,
pre-vaccination. Blinding was maintained by using designated
nurses or physicians to administer the study vaccines to the
subjects, while the investigators and other investigative site
personnel remained blinded.
2.3. Safety monitoring
Each subject was observed for 30 min post-vaccination for any
local or systemic reactions, or anaphylaxis. Oral or axillary
temperature was recorded, and subjects were given diary cards
to record solicited local (pain, erythema, and induration) or
systemic (chills, nausea, malaise, myalgia, arthralgia, headache,
and rash) reactions that occurred between day 1 and day 7. Any
adverse events (AEs) requiringmedical attentionwere recorded for
1 month post-vaccination, and any medically signiﬁcant and
serious AEs (SAEs) were recorded for 6 months post-vaccination.
2.4. Serology
Blood samples (20 ml) were obtained pre-vaccination and at 1-
month post-vaccination. The immunogenicity of the study
vaccines was evaluated by serum bactericidal activity using
human complement (hSBA) for meningococcal serogroups A, C,
W-135, and Y according to methods described previously.24
For comparisons of the immunogenicity of the vaccines, three
immunologic endpoints were deﬁned. For each serogroup, these
endpoints included the post-vaccination hSBA geometric mean
titer (GMT), the proportion of subjects with a post-vaccination
hSBA titer 1:8, and the proportion of seroresponders. Seror-
esponse was a composite endpoint that incorporated two
categories of pre-vaccination immune status: for initially seroneg-
ative subjects, i.e., with a baseline hSBA titer <1:4, seroresponse
was deﬁned as a post-vaccination hSBA titer of 1:8; for those
initially seropositive, with a baseline hSBA titer1:4, seroresponse
was deﬁned as at least a 4-fold increase in the pre-vaccination titer.
2.5. Statistical methods and analyses
The immunogenicity of MenACWY-CRM was considered non-
inferior to the immunogenicity of MenACWY-D for any of the four
serogroups, if the lower limit (LL) of the two-sided 95% conﬁdence
interval (CI) around the difference (MenACWY-CRM minus
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or percentage of subjects with an hSBA titer 1:8 for that
serogroup was greater than10%; superiority was deﬁned as an LL
greater than 0%. Similarly, for GMTs, non-inferiority was based on
the LL of the two-sided 95% CI around the ratio of the geometric
means (MenACWY-CRM:comparator) >0.5; superiority was de-
ﬁned as an LL >1.0.
The vaccine group differences in the percentage of subjects
achieving a seroresponse or an hSBA titer 1:8 were calculated
using binomial distribution. When constructing two-sided 95% CI
for the difference between MenACWY-CRM and the comparator in
the proportion of subjects with a response, the associated 95% CI
was constructed using the differences of two percentages based on
the Chi-squaremethod.28 Vaccine group ratios of GMTs, alongwith
the 95% CI for the ratio, were based on the estimate of the
difference in least squaremeans from an analysis of variancewhich
included vaccine group and center as ﬁxed effects in the model.
Titers were transformed to a log10 basis for the analyses and the
results were then back-transformed to provide the GMTs and
associated difference and CI.
The study was powered to assess non-inferiority in the 19–55
years age cohort; the analysis of the 56–65 years age cohort was
exploratory. The per protocol population was used for the analyses
and consisted of subjects who received a vaccine, provided
evaluable sera pre- and post-vaccination, and had no major
protocol violations, which may have precluded the assessment of
immunogenicity (i.e., corticosteroid use). Statistical analyses were
performed using SAS software, version 9.1 or higher (SAS Institute,
Cary, NC, USA).Table 1
Subject demographics for the total enrolled population
19–55 years of age
MenACWY-CRM (n=1606) MenACWY
Mean age, years (SD) 34.6 (10.1) 34.8 (10.4)
Male, n (%) 514 (32) 272 (30)
Ethnicity, n (%)
Asian 1 (<1) 1 (<1)
Black 135 (8) 109 (12)
Caucasian 249 (16) 127 (14)
Hispanic 1217 (76) 658 (73)
Other 4 (<1) 3 (<1)
MenACWY-CRM, quadrivalent meningococcal CRM197 conjugate vaccine; MenACWY-D
unconjugated quadrivalent meningococcal polysaccharide vaccine; SD, standard deviat
Table 2
Subject demographics for the per protocol immunogenicity population
19–55 years of age
MenACWY-CRM (n=183) MenACWY
Mean age, years (SD) 36.5 (11.2) 36.4 (10.9
Male, n (%) 32 (17) 42 (23)
Ethnicity, n (%)
Asian 0 (0) 0 (0)
Black 52 (28) 57 (31)
Caucasian 0 (0) 0 (0)
Hispanic 131 (72) 127 (69)
Other 0 (0) 0 (0)
Baseline hSBA titer 1:8
A 8 10
C 21 25
W-135 60 66
Y 22 29
MenACWY-CRM, quadrivalent meningococcal CRM197 conjugate vaccine; MenACWY-D
unconjugated quadrivalent meningococcal polysaccharide vaccine; SD, standard deviat3. Results
3.1. Subject characteristics
Subject demographics were well matched between all groups
(Tables 1 and 2). Of the 2831 subjects enrolled, 2785 completed the
study in line with the protocol (Figure 1). Overall, 46 subjects
withdrew from the study; six withdrew consent, 28 were lost to
follow-up, 11 were enrolled inappropriately, and one died
(unrelated to the study vaccines).
3.2. Safety and tolerability
3.2.1. Local reactions
Frequencies of subjects reporting any local reaction were
similar in both age groups; 46% of MenACWY-CRM and 50% of
MenACWY-D recipients in the 19–55 years age group, and 43% of
MenACWY-CRM and 40% of MPSV4 recipients in the 56–65 years
age group, experienced local reactions (Table 3). The most
frequently reported local reaction was pain, reported by 40% of
MenACWY-CRM recipients and 44% of MenACWY-D recipients in
the 19–55 years age group, and 32% of MenACWY-CRM and 31% of
MPSV4 recipients in the 56–65 years age group.
The percentages of subjects reporting erythema and induration
were similar between vaccine groups and within age groups
(erythema: 19–55 years of age – MenACWY-CRM 13%, MenACWY-
D 12%; 56–65 years of age – MenACWY-CRM 19%, MPSV4 12%.
Induration: 19–55 years of age –MenACWY-CRM 11%, MenACWY-
D 13%; 56–65 years of age – MenACWY-CRM 18%, MPSV4 16%).56–65 years of age
-D (n=899) MenACWY-CRM (n=217) MPSV4 (n=109)
60.1 (2.7) 60.1 (2.6)
54 (25) 30 (28)
1 (<1) 0
18 (8) 8 (7)
38 (18) 23 (21)
158 (73) 77 (71)
2 (<1) 1 (<1)
, quadrivalent meningococcal polysaccharide–protein conjugate vaccine; MPSV4,
ion.
56–65 years of age
-D (n=184) MenACWY-CRM (n=84) MPSV4 (n=41)
) 60.0 (2.5) 59.6 (2.3)
15 (18) 9 (22)
0 (0) 0 (0)
15 (18) 7 (17)
0 (0) 0 (0)
69 (82) 34 (83)
0 (0) 0 (0)
11 7
21 17
67 67
20 27
, quadrivalent meningococcal polysaccharide–protein conjugate vaccine; MPSV4,
ion; hSBA, serum bactericidal activity using human complement.
[(Figure_1)TD$FIG]
Figure 1. Subject disposition ﬂowchart.
MenACWY-CRM, quadrivalent meningococcal CRM197 conjugate vaccine; MenACWY-D, quadrivalent meningococcal polysaccharide-protein conjugate vaccine; MPSV4,
unconjugated quadrivalent meningococcal polysaccharide vaccine; SAE, serious adverse event.
aInappropriate enrollments included: subject with a pacemaker; vaccination received 15 days before the day of enrollment; subject had doubts about previous
meningococcal vaccination; subject was pregnant.
bInappropriate enrollments included: subject had Sheehan’s syndrome; subject planning to leave study area before the end of the study period; subject had doubts about
previous meningococcal vaccination; subject did not want to use any contraceptionmethod; subject was pregnant; subject taking methotrexate due to rheumatoid arthritis;
subject had supraventricular tachycardia.
cUnrelated to the study vaccine.
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reported a local reaction as severe or >50 mm.
3.2.2. Systemic reactions
The percentages of subjects reporting any systemic reaction
were also similar between vaccine groups and within age groups
(19–55 years of age: MenACWY-CRM 39%, MenACWY-D 43%; 56–
65 years of age:MenACWY-CRM39%,MPSV4 40%) (Table 3). Across
the vaccine groups, the most commonly reported systemic
reactions were headache, malaise, and myalgia. In the 19–55
years age group, these were reported by 27%, 19%, and 12%,
respectively, of MenACWY-CRM recipients, and by 29%, 21%, and
15%, respectively, of MenACWY-D recipients (Table 3). In the 56–
65 years age group, these were reported by 24%, 23%, and 18%,
respectively, of MenACWY-CRM recipients, and by 28%, 18%, and
10%, respectively, of MPSV4 recipients (Table 3).
3.2.3. Adverse events
In the 19–55 years age group, the percentage of subjects
experiencing any unsolicited AEs was similar between vaccine
groups (MenACWY-CRM 19%; MenACWY-D 21%). In the 56–65
years age group, the percentage of subjects experiencing any
unsolicited AEs was slightly higher for MenACWY-CRM recipients
(25%) than MPSV4 recipients (15%). The percentage of subjectsexperiencing possibly or probably related AEswas similar between
the vaccine and age groups (9%) except for MenACWY-CRM (15%)
in the 56–65 years age group.
One SAE occurred that was considered by the study investigator
to be possibly related to the study vaccination. This was in a 34-
year-old woman who had a spontaneous abortion 44 days after
vaccination with MenACWY-CRM. She had a negative urine
pregnancy test at the time of study entry. In the 56–65 years
age group, one death occurred due to hypovolemic shock following
a surgical procedure and was not considered vaccine-related.
3.2.4. Immunogenicity
The immune responses to MenACWY-CRM were generally
higher in both age groups when compared with the respective
comparator vaccines.
3.2.5. 19–55 years age group
The seroresponse rate endpoint estimates were numerically
higher in the MenACWY-CRM group than in the MenACWY-D
group for all serogroups (A: 78% vs. 77%; C: 83% vs. 81%; W-135:
66% vs. 53%; Y: 80% vs. 58%) (Table 4). Non-inferiority of the
immune response, assessed as the number of subjects with a
seroresponse to MenACWY-CRM compared with the number
achieving a seroresponse to MenACWY-D, was demonstrated for
Table 3
Solicited local and systemic reactions at 7-days post-vaccination with MenACWY-CRM or MenACWY-D in subjects aged 19–55 years, and MenACWY-CRM or MPSV4 in
subjects aged 56–65 years
Reactogenicity Subjects, n (%)
19–55 years of age 56–65 years of age
MenACWY-CRM (n=1588) MenACWY-D (n=882) MenACWY-CRM (n=216) MPSV4 (n=109)
Any local reaction
Any 729 (45.9) 439 (49.8) 92 (42.6) 44 (40.4)
Severe 60 (3.8) 37 (4.2) 12 (5.6) 2 (1.8)
Pain
Any 632 (39.8) 392 (44.4) 69 (31.9) 34 (31.2)
Severe 41 (2.6) 29 (3.3) 8 (3.7) 2 (1.8)
Erythema
Any 207 (13.0) 105 (11.9) 41 (19.0) 13 (12.0)a
>50 mm 17 (1.1) 7 (0.8) 6 (2.8) 0 (0)
Induration
Any 179 (11.3) 115 (13.0) 39 (18.1) 17 (15.7)a
>50 mm 13 (0.8) 10 (1.1) 4 (1.9) 0 (00)
Any systemic reaction
Any 616 (38.8) 375 (42.5) 84 (38.9) 44 (40.4)
Severe 95 (6.0) 46 (5.2) 14 (6.5) 9 (8.3)
Chills
Any 124 (7.8) 70 (7.9) 26 (12.0) 6 (5.5)
Severe 19 (1.2) 5 (0.6) 5 (2.3) 3 (2.8)
Nausea
Any 112 (7.1) 77 (8.7) 20 (9.3) 8 (7.3)
Severe 10 (0.6) 4 (0.5) 2 (0.9) 1 (0.9)
Malaise
Any 309 (19.5) 186 (21.1) 50 (23.1) 20 (18.3)
Severe 43 (2.7) 12 (1.4) 9 (4.2) 6 (5.5)
Myalgia
Any 197 (12.4) 131 (14.9) 39 (18.1) 11 (10.1)
Severe 25 (1.6) 10 (1.1) 3 (1.4) 5 (4.6)
Arthralgia
Any 118 (7.4) 76 (8.6) 25 (11.6) 11 (10.1)
Severe 16 (1.0) 7 (0.8) 2 (0.9) 4 (3.7)
Headache
Any 421 (26.5) 254 (28.8) 52 (24.1) 30 (27.5)
Severe 49 (3.1) 26 (2.9) 6 (2.8) 5 (4.6)
Fever (38 8C)
Any 56 (3.5)b 31 (3.5) 6 (2.8) 3 (2.8)
39 8C 14 (0.9) 9 (1.0) 4 (1.9) 1 (0.9)
Other
Analgesic/antipyretic used 250 (15.7) 148 (16.8)c 25 (11.6) 14 (12.8)
Stayed at home 75 (4.7)d 46 (5.2)e 14 (6.5)f 6 (5.6)a
MenACWY-CRM, quadrivalent meningococcal CRM197 conjugate vaccine; MenACWY-D, quadrivalent meningococcal polysaccharide–protein conjugate vaccine; MPSV4,
unconjugated quadrivalent meningococcal polysaccharide vaccine.
Severe, unable to perform normal daily activities.
an=108; bn=1587; cn=881; dn=1585; en=880; fn=214.
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serogroups W-135 and Y (Table 4).
The GMTs showed a large increase for all four serogroups in
both vaccine groups, but were consistently higher in the
MenACWY-CRM group (A: 77 vs. 52; C: 114 vs. 88; W-135: 159
vs. 112; Y: 95 vs. 40), and the ratio of GMTs met the pre-speciﬁedTable 4
Immunogenicity against meningococcal serogroups A, C, W-135, and Y at 1-month pos
Serogroup Seroresponse hSBA titer 1:8
MenACWY-CRM Men
ACWY-D
Group
difference
(95% CI)
Men
ACWY-CRM
Men
ACW
A 78 (n=179) 77 (n=182) 0 (8–9)a 81 (n=179) 80 (
C 83 (n=180) 81 (n=183) 2 (6–10)a 88 (n=180) 92 (
W-135 66 (n=178) 53 (n=180) 12 (2–22)b 98 (n=178) 93 (
Y 80 (n=181) 58 22 (13–31)b 88 (n=181) 76
hSBA, serum bactericidal activity using human complement; MenACWY-CRM, quad
meningococcal polysaccharide–protein conjugate vaccine; CI, conﬁdence interval. aNon-
criterionmet (lower limit of the two-sided 95% CI>0%). cNon-inferiority criterionmet (lo
two-sided 95% CI >1.0).criteria for non-inferiority for all four serogroups, and met the
criteria for superiority for serogroup Y (Table 4 and Figure 2).
When assessed as the proportion of subjects with an hSBA titer
1:8 at 1-month post-vaccination, the immune response to
MenACWY-CRM met the criteria for non-inferiority compared
with MenACWY-D for serogroups A, W-135, and Y, and met thet-vaccination with MenACWY-CRM or MenACWY-D in subjects aged 19–55 years
Geometric mean titer
Y-D
Group
difference
(95% CI)
Men
ACWY-CRM
Men
ACWY-D
Post-vaccination
group ratio (95% CI)
n=182) 1 (7–9)a 77 (n=179) 52 (n=182) 1.5 (0.98–2.3)c
n=183) 5 (11–2) 114 (n=180) 88 (n=183) 1.3 (0.85–1.97)c
n=180) 5 (1–10)b 159 (n=178) 112 (n=180) 1.42 (0.99–2.03)c
11 (4–19)b 95 (n=181) 40 2.37 (1.56–3.6)d
rivalent meningococcal CRM197 conjugate vaccine; MenACWY-D, quadrivalent
inferiority criterion met (lower limit of the two-sided 95% CI >10%). bSuperiority
wer limit of the two-sided 95% CI>0.5). dSuperiority criterionmet (lower limit of the
[(Figure_2)TD$FIG]
Figure 2. Reverse cumulative distribution of hSBA titers in subjects (A)–(D) 19–55 years of age or (E)–(H) 56–65 years of age against meningococcal serogroups A, C, W-135,
and Y, pre-vaccination and 1-month post-vaccination with MenACWY-CRM, MenACWY-D, or MPSV4.
hSBA, serum bactericidal activity using human complement; MenACWY-CRM, quadrivalent meningococcal CRM197 conjugate vaccine; MPSV4, unconjugated quadrivalent
meningococcal polysaccharide vaccine.
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Table 5
Immunogenicity against meningococcal serogroups A, C, W-135, and Y at 1-month post-vaccination with MenACWY-CRM or MPSV4 in subjects aged 56–65 years
Serogroup Seroresponse hSBA titer 1:8 Geometric mean titer
Men
ACWY-CRM
MPSV4
(n=41)
Group
difference
(95% CI)
Men
ACWY-CRM
(n=84)
MPSV4
(n=41)
Group
difference
(95% CI)
Men
ACWY-CRM
(n=84)
MPSV4
(n=41)
Post-vaccination
group ratio
(95% CI)
A 86 (n=83) 61 25 (9–41) 87 (n=83) 63 23 (8–40) 111 (n=83) 21 5.4 (2.47–12)
C 83 73 10 (4–27) 90 83 8 (4–23) 196 86 2.27 (1.05–4.95)
W-135 61 (n=82) 54 (n=39) 7 (11–26) 94 (n=82) 95 (n=39) 1 (9–11) 164 (n=82) 132 (n=39) 1.24 (0.64–2.42)
Y 77 54 24 (6–41) 88 68 20 (5–36) 121 28 4.25 (1.89–9.56)
hSBA, serum bactericidal activity using human complement; MenACWY-CRM, quadrivalent meningococcal CRM197 conjugate vaccine; MPSV4, unconjugated quadrivalent
meningococcal polysaccharide vaccine; CI, conﬁdence interval.
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(Table 4).
3.2.6. 56–65 years age group
The percentage of seroresponders was consistently higher in
the MenACWY-CRM group than in the MPSV4 group, for all
serogroups (A: 86% vs. 61%; C: 83% vs. 73%;W-135: 61% vs. 54%; Y:
77% vs. 54%) (Table 5). Geometric mean titers were also
consistently higher in the MenACWY-CRM group than in the
MPSV4 group for all serogroups (A: 111 vs. 21; C: 196 vs. 86; W-
135: 164 vs. 132; Y: 121 vs. 28) with GMTs several-fold higher (5-
fold higher for serogroup A) in the MenACWY-CRM group than in
the MPSV4 group (Table 5).
Using the criteria of subjects with an hSBA titer 1:8, the
immune response was higher in theMenACWY-CRM group than in
the MPSV4 group for serogroups A, C, and Y (Table 5).
4. Discussion
The investigational quadrivalent meningococcal conjugate
vaccine, MenACWY-CRM, was well tolerated and had comparable,
or statistically higher, immune responses compared with the two
currently licensed quadrivalent meningococcal vaccines available
for adults aged 19 to 65 years (MenACWY-D for subjects 11–55
years of age and MPSV4 for subjects 56–65 years of age). The
results from this study are consistent with other recently reported
data, in which the immunogenicity of MenACWY-CRM and
MenACWY-D were compared.27
MenACWY-D (Menactra), the only other licensed quadrivalent
meningococcal conjugate vaccine, is currently licensed for use in
subjects aged 2–55 years in Canada and the USA.While the clinical
relevance of the ﬁndings requires further study, in subjects aged
19–55 years, the immune response following vaccination with
MenACWY-CRM nevertheless demonstrated favorable immuno-
genicity compared with that of MenACWY-D, for each of the
clinical endpoints. These ﬁndings may reﬂect differences in the
carrier proteins used for conjugation: CRM197 and diphtheria
toxoid, respectively. These results are consistent with those
observed in infants and toddlers vaccinated with Haemophilus
inﬂuenzae type b (Hib),29 in which a vaccine using the diphtheria
toxoid as the carrier protein was less immunogenic than a vaccine
using CRM197. However, diphtheria toxoid is no longer used as a
carrier protein in any currently licensed infant vaccines. Other
differences between the vaccines include selective sizing of the
oligosaccharides before conjugation (MenACWY-CRM) and the
conjugation chemistry employed.30
The only available quadrivalent meningococcal vaccines for
use outside North America are unconjugated polysaccharide
vaccines, and at this time they are the only vaccines licensed for
use in persons >55 years of age. Here, we have shown that
immune responses following vaccination with MenACWY-CRM
were higher for most meningococcal serogroups compared withthose following vaccination withMPSV4 (Menomune) in subjects
aged 56–65 years. This difference was particularly notable for
serogroups A and Y, where GMTs induced by MenACWY-CRM
exceeded those induced byMPSV4 bymore than 4-fold (111 vs. 21
for serogroup A; 121 vs. 28 for serogroup Y). The clinical relevance
of higher GMTs is unclear, but it is worth noting that higher
proportions of participants achieved the putative seroprotective
hSBA titer 1:8 against serogroups W-135 and Y in the 19–55
years age group, and serogroups A and Y in the 56–65 years age
group, compared with the vaccines currently available for these
populations. Although most subjects >55 years of age are
presumably not naı¨ve to these meningococcal antigens, these
results are consistent with those from several other studies of
vaccination of adults or the elderlywith conjugate (pneumococcal
or H. inﬂuenzae) vaccines relative to their unconjugated puriﬁed
polysaccharide vaccine counterparts.31–33 Outside Canada and
the USA, the meningococcal quadrivalent polysaccharide vaccine
is the only vaccine available that provides broad serogroup
protection against meningococcal disease, particularly in high
risk groups such as travelers and the military. Given the dynamic
epidemiology of meningococcal disease and the limitations of the
polysaccharide vaccine previously discussed, broad protection for
all ages is important, as one cannot rely on vaccines that only
target local epidemiology to protect against serogroups encoun-
tered in other countries. These data indicate thatMenACWY-CRM
may provide an enhanced immune response to the currently
available options.
There are three currently licensed meningococcal serogroup C
conjugate vaccines (Meningitec, Wyeth Vaccines, Philadelphia, PA,
USA; Menjugate, Novartis Vaccines, Siena, Italy; and NeisVac-C,
Baxter Healthcare, Beltsville, MA, USA) that are available for use in
children <2 years of age. However, there is no quadrivalent
vaccine, either conjugate or polysaccharide, available for use in this
age group (which has the highest incidence of meningococcal
disease). MenACWY-CRM has previously been shown to be
immunogenic and well tolerated in infants from 2 months of
age,23,24 children,25 adolescents,26 and adults from 19 to 65 years
of age in this study. As such, and in view of the non-inferiority to
the current options demonstrated in this report, it is signiﬁcant
that a vaccine which has been shown to be immunogenic in all age
groups from infants to the elderly is non-inferior to a vaccine only
licensed for the 2–55 years age group. MenACWY-CRM has the
potential to expand meningococcal protection from currently
available options for age and serogroup, and provide a public
health beneﬁt over and above currently available vaccines.
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